Table 5.

Commercial Qualitative and Quantitative HCV Molecular Assays (Modified from Ghani et al. Hepatology 2009)

Qualitative Assay	Application	LOD	Technique	Type Amplification
AmpliScreen 2.0 (Roche Molecular System)	Blood screening	< 50 UI/ml	Semi-automated rtPCR	Target
Amplicor HCV 2.0 (Roche Molecular System)	To Confirm active infection	60 UI/ml in serum 50 UI/ml in EDTA	Manual rtPCR	Target
Cobas Amplicor Monitor HCV 2.0 (Roche Molecular System)	To Confirm active infection	50 UI/ml in EDTA 60 UI/ml in serum	Semi-automated rtPCR	Target
Versant HCV RNA (Siemens Healthcare Diagnotics)	To Confirm active infection/ Blood screening	5 IU/mll	Semi-automated TMA	Target
Procleix HIV/HCV assay (Gen Probe)	To Confirm active infection/ Blood screening	<50 IU/ml	Manual TMA	Target
Procleix Ultrio assay (Gen Probe)	To Confirm active infection/ Blood screening	<50 IU/ml	Automated TMA	Target
Quantitative Assay	LOD and Dynamic Range (IU/L)	1 IU/L conversion	Technique	Type Amplification
Amplicor HCV Monitor 2.0 (Roche Molecular System)	600 (600-500,000)	0.9 copies/ml	Manual competitive rtPCR	Target
Cobas Amplicor Monitor HCV 2.0 (Roche Molecular System)	600 (600-500,000)	2.4 copies/ml	Semi-automated competitive rtPCR/ automated	Target
Cobas AmliPrep/Cobas TaqMan HCV (Roche Molecular System)	15(43—69,000,000)	2.7 copies/ml	Semi-automated compeitive rtPCR	Target
Versant HCV RNA 3.0 Quantitative assay (Siemens Health Care Diagnostics)	520 (615-700,000)	5.2 copies/ml	Semi-automated “branched DNA” Assay	Signal
LCx HCV RNA Quantitative assay (Abbott Laboratories)	23 (25-2,300,000)	4.3 copies/ml	Semi-automated Competitive rtPCR	Target
SuperQuant (National Genetic Institute)	100 (600-1,470,000)	3.4 copies/ml	Semi-automated Competitive rtPCR	Target
Abbott RealTime (Abbott Molecular Diagnostics)	12 (12-100,000,000)	Not available	Automated rtPCR	Target